| | An assessment of the utility of the yeast GreenScreen assay in |
| | 0,11 | | MB | pharmaceutical screening |
| | 6 | | stron |
| | 6619 | | ID | University of Manchester |
| | 2005 | | rok |
| | In this paper we describe an initial reproducibility study of 12 proprietary compounds followed by |
| | the assessment of 51 marketed pharmaceuticals and, lastly, a summary of the data so far from |
| | 2698 proprietary compounds from the Johnson & Johnson (J&J) compound library, in the yeast |
| | GreenScreen assay (GSA). In this assay, a reporter system in the yeast cells employs the DNA |
| | damage inducible promoter of the RAD54 gene, fused to the extremely stable green fluorescent |
| | protein (GFP). The assay proved to be very robust, the Excel templates provided by Gentronix with |
| | the assay interfaced well with in-house J&J systems with little adaptation, the assay was very |
| | rapid to perform and used very little compound. The results confirm previous work which suggests |
| | that the yeast GSA detects different classes of genotoxic compounds to the Ames assay and as a |
| | result can help screen out important genotoxic compounds at the pre-regulatory test phase that are |
| | missed by Ames-test-based screens alone. A combination of SAR evaluati on of genotoxicity plus |
| | an Ames-test-based screen and the GSA provides a powerful pre-regulatory test battery to aid in |
| | the selection of successful drug candidates. |